Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. Melphalan-prednisone in the phase III VISTA trial in multiple myeloma

  1. Delforge, M.
  2. Terpos, E.
  3. Richardson, P.G.
  4. Shpilberg, O.
  5. Khuageva, N.K.
  6. Schlag, R.
  7. Dimopoulos, M.A.
  8. Kropff, M.
  9. Spicka, I.
  10. Petrucci, M.T.
  11. Samoilova, O.S.
  12. Mateos, M.-V.
  13. Magen-Nativ, H.
  14. Goldschmidt, H.
  15. Esseltine, D.-L.
  16. Ricci, D.S.
  17. Liu, K.
  18. Deraedt, W.
  19. Cakana, A.
  20. Van de Velde, H.
  21. San Miguel, J.F.
Revista:
European Journal of Haematology

ISSN: 0902-4441 1600-0609

Any de publicació: 2011

Volum: 86

Número: 5

Pàgines: 372-384

Tipus: Article

DOI: 10.1111/J.1600-0609.2011.01599.X GOOGLE SCHOLAR